首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   632篇
  免费   19篇
  国内免费   5篇
耳鼻咽喉   1篇
儿科学   21篇
妇产科学   18篇
基础医学   42篇
口腔科学   2篇
临床医学   43篇
内科学   56篇
皮肤病学   19篇
神经病学   11篇
特种医学   5篇
外国民族医学   1篇
外科学   11篇
综合类   158篇
预防医学   48篇
药学   155篇
中国医学   35篇
肿瘤学   30篇
  2023年   1篇
  2021年   1篇
  2020年   8篇
  2019年   14篇
  2018年   16篇
  2017年   8篇
  2016年   13篇
  2015年   10篇
  2014年   25篇
  2013年   38篇
  2012年   23篇
  2011年   42篇
  2010年   49篇
  2009年   49篇
  2008年   36篇
  2007年   46篇
  2006年   51篇
  2005年   41篇
  2004年   25篇
  2003年   25篇
  2002年   20篇
  2001年   17篇
  2000年   10篇
  1999年   13篇
  1998年   5篇
  1997年   7篇
  1996年   8篇
  1995年   3篇
  1994年   2篇
  1993年   4篇
  1992年   3篇
  1991年   2篇
  1990年   1篇
  1989年   3篇
  1988年   1篇
  1987年   1篇
  1986年   2篇
  1985年   7篇
  1984年   5篇
  1983年   4篇
  1982年   4篇
  1981年   6篇
  1980年   2篇
  1979年   1篇
  1978年   3篇
  1976年   1篇
排序方式: 共有656条查询结果,搜索用时 31 毫秒
1.
目的比较康复新液与浓替硝唑含漱液对低危妊娠滋养细胞肿瘤MTX化疗性口腔溃疡的临床疗效。方法我院2013年12月至2015年12月收治的低危滋养细胞肿瘤患者,选取50例合并口腔溃疡患者作为研究对象,分为2组,每组25例。治疗组:给予康复新溶液,对照组给予浓替硝唑含漱液,评价两组疗效和毒副反应。结果康复新液组治疗有效率为96%,浓替硝唑组为80%,两组比较差异有统计学意义(P<0.05)。口腔溃疡的愈合情况比较:治疗组愈合时间为(4.3±1.9)d;对照组为(7.1±2.6)d,两组比较差异有统计学意义(P<0.05)。所有患者均未发生与康复新液和浓替硝唑相关的不良反应。结论康复新液治疗低危妊娠滋养细胞肿瘤患者相关化疗性口腔溃疡安全有效,值得临床推广。  相似文献   
2.
房乾 《海峡药学》2016,(7):257-260
为实现rhCG融合蛋白在CHO细胞中的高效表达,构建两个不同的 His-tag rhCG 融合蛋白真核表达载体,通过瞬时转染比较两个载体在CHO-dhfr-细胞中的表达量,选择表达量较高的载体稳定转染CHO-dhfr -,并采用氨甲喋呤( MTX)进行加压筛选高表达单克隆细胞株。加压后,表达量由1日1300mIU? mL -1提高至18000mIU? mL -1(以106个细胞计)。该克隆株经传代50代以后,rhCG表达量未发生明显变化,表明该克隆为稳定克隆株。用Ni+螯合亲和层析及凝胶过滤层析分离纯化表达产物,获得纯度大于99%的rhCG融合蛋白,SDS-PAGE电泳及 Western Blot结果表明rhCG得到正确及完整的表达,生物学活性测定结果表明样品比活为11000IU? mg -1。  相似文献   
3.
Background: Chemotherapy is typically used to treat choriocarcinoma, but a small proportion of tumors develop resistance to chemotherapy. Similarly, methotrexate (MTX) is a first-line chemotherapy used to treat choriocarcinoma; although ~30% of patients are drug-resistant for MTX mono-therapy. Thus, we sought to elucidate the mechanism of chemotherapeutic-resistance of MTX.Methods: RNA interference technology, colony formation, and MTT assays were used to investigate the role of aldo-keto reductase family 1, member C3 (AKR1C3) in MTX resistance in choriocarcinoma cells.Results: AKR1C3 expression was higher in JeG-3R cells compared to JeG-3 cells and targeted inhibition of AKR1C3 expression with shRNA suppresses growth of choriocarcinoma cells as measured by colony formation and MTT assays. Overexpression of AKR1C3 increased chemotherapeutic resistance in JeG-3 cells. Furthermore, AKR1C3 silencing increases sensitivity to MTX in JeG-3R choriocarcinoma cells. Increasing MTX sensitivity spears to be related to DNA damage induction by increased reactive oxygen species (ROS), apoptosis, and cell cycle arrest.Conclusions: Data show that AKR1C3 is critical to the development of methotrexate resistance in choriocarcinoma and suggest that AKR1C3 may potentially serve as a therapeutic marker for this disease.  相似文献   
4.
5.
Gene amplification, which involves the two major topographical structures double minutes (DMs) and homegeneously stained region (HSR), is a common mechanism of treatment resistance in cancer and is initiated by DNA double-strand breaks. NHEJ, one of DSB repair pathways, is involved in gene amplification as we demonstrated previously. However, the involvement of homologous recombination, another DSB repair pathway, in gene amplification remains to be explored. To better understand the association between HR and gene amplification, we detected HR activity in DM- and HSR-containing MTX-resistant HT-29 colon cancer cells. In DM-containing MTX-resistant cells, we found increased homologous recombination activity compared with that in MTX-sensitive cells. Therefore, we suppressed HR activity by silencing BRCA1, the key player in the HR pathway. The attenuation of HR activity decreased the numbers of DMs and DM-form amplified gene copies and increased the exclusion of micronuclei and nuclear buds that contained DM-form amplification; these changes were accompanied by cell cycle acceleration and increased MTX sensitivity. In contrast, BRCA1 silencing did not influence the number of amplified genes and MTX sensitivity in HSR-containing MTX-resistant cells. In conclusion, our results suggest that the HR pathway plays different roles in extrachromosomal and intrachromosomal gene amplification and may be a new target to improve chemotherapeutic outcome by decreasing extrachromosomal amplification in cancer.  相似文献   
6.

Background:

Intrathecal methotrexate (ITMTX) is an important component in the treatment as well as prophylaxis of leukemia/lymphoma. ITMTX can cause chemical meningitis characterized by vomiting, headache, and fever lasting 2-5 days with spontaneous resolution of symptoms which differentiates this syndrome from bacterial meningitis.

Objective:

This prospective observational study was carried out to determine incidence of post-ITMTX syndrome in patients receiving prophylactic ITMTX as part of Berlin-Frankfurt-Munster (BFM) protocol.

Materials and Methods:

Patients aged 15-50 years receiving BFM 90 or BFM 95 protocol for acute lymphoblastic leukemia or lymphoblastic lymphoma were followed up for post-ITMTX syndrome, defined as vomiting, headache and fever between 38° and 39°C following ITMTX.

Results:

Thirty-three patients received a total of 297 courses of ITMTX. Of the 297 doses of ITMTX, 20 episodes (6.7%) of post-ITMTX syndrome were observed. The incidence of post-ITMTX syndrome was highest after the second dose of ITMTX (24%). The most common symptom of post-ITMTX syndrome was headache which was seen in 17 (85%) patients. Seventeen (85%) patients had vomiting, 10 (50%) patients had fever, and 4 (20%) patients had backache. Meningeal signs were present in 2 (10%) patients.

Conclusions:

Post-ITMTX syndrome is not uncommon in adult patients receiving prophylactic ITMTX for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. Patients develop a toxic syndrome closely mimicking acute bacterial meningitis but spontaneous recovery is seen without any neurological sequelae.  相似文献   
7.
Heart involvement – often asymptomatic – is largely underestimated in patients with systemic autoimmune diseases (SADs). Cardiovascular events are more frequent in patients with SADs compared to the general population, owing to the consequences of inflammation and autoimmunity and to the high prevalence of traditional risk factors. Coronary microvascular disease (CMD) is a form of cardiac involvement that is increasingly recognised yet still largely neglected. CMD, the incapacity of the coronary microvascular tree to dilate when myocardial oxygen demand increases or when there is a microvascular spasm (or subclinical myocarditis), is increasingly reported because of the widespread use of new cardiac imaging tools, even in a subclinical phase. The assessment of myocardial coronary flow reserve (CFR) emerged as the most effective clinical tool to detect microvascular damage. The potential causes of microvascular damage, molecular and cellular inflammation along with a pathological CD39-CD73 axis, need always to be considered because data show that they play a role in the occurrence of acute coronary syndromes, heart failure and arrhythmias, even in the early asymptomatic stage. Data suggest that controlling disease activity by means of methotrexate, biologic drugs, antimalarial medications, statins and aspirin, according to indication, might reduce the cardiovascular risk related to macrovascular and microvascular damage in most patients with SADs, provided that they are used early and timely to control diseases. The need of new biomarkers and a careful assessment of myocardial CFR emerged as the most effective clinical tool to detect microvascular damage.  相似文献   
8.
9.
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and adolescents. Immunomodulatory drugs are used frequently in its treatment. Using the nominal group technique (NGT) and Delphi method, we created a multidisciplinary, evidence- and consensus-based treatment guideline for JIA based on a systematic literature analysis and three consensus conferences. Conferences were headed by a professional moderator and were attended by representatives who had been nominated by their scientific societies or organizations. 15 statements regarding drug therapy, symptomatic and surgical management were generated. It is recommended that initially JIA is treated with NSAID followed by local glucocorticoids and/or methotrexate if unresponsive. Complementing literature evidence with long-standing experience of caregivers allows creating guidelines that may potentially improve the quality of care for children and adolescents with JIA.  相似文献   
10.
类风湿性关节炎联合用药的研究   总被引:1,自引:0,他引:1  
庞泽文 《中国当代医药》2012,19(11):32-33,35
目的探讨联合用药治疗类风湿性关节炎。方法把36例患者任意分为甲乙两个小组,甲组18例患者接受甲氨喋呤与青霉胺联合用药的治疗方式,乙组18例患者则接受联合甲氨喋呤与羟氯喹的用药方式。结果甲乙两个小组患者在接受药物联合治疗之前各项指标之间不存在统计学上的差异,在接受药物联合治疗之后,每一项指标的值都得到了明显降低,P值小于0.05,差异有统计学意义。甲乙两个小组临床治疗效果有效的例数均是17例,占小组总人数的94.44%;无效只有1例,占小组总人数的5.56%。两个小组临床治疗的综合评价并不存在统计学上的差异,其中P值大于0.05。甲组药物引发不良反应的概率及症状的严重程度都明显低于乙组。结论甲乙两个小组联合用药策略都可以获得令人满意的临床治疗效果,疗效的综合评价在整体上是一样的。联合用药治疗类风湿性关节炎的根本要求是结合具有差异作用机制的抗风湿药,在不同的时间段中预防组织与细胞受到伤害,实现获得协同或相加的临床疗效,而不良反应不重复。在临床上选择联合应用抗风湿药对类风湿性关节炎患者进行治疗,可以有效改善其症状,抑制骨质发生损坏,并控制病情的发展。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号